mitoxantrone has been researched along with Lymph Node Metastasis in 48 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim was to determine the recommended dose of combined chemotherapy with mitoxantrone and uracil/tegafur (Phase I part) and to clarify its efficacy and safety in patients with advanced hepatocellular carcinoma at the recommended dose (Phase II part)." | 9.15 | A phase I/II study of combined chemotherapy with mitoxantrone and uracil/tegafur for advanced hepatocellular carcinoma. ( Furuse, J; Ikeda, M; Ishii, H; Mitsunaga, S; Morizane, C; Nakachi, K; Okusaka, T; Suzuki, E; Ueno, H, 2011) |
| "Vinorelbine and mitoxantrone have both been demonstrated to have significant antitumor activity in patients with breast cancer." | 9.12 | Mitoxantrone plus vinorelbine in pretreated patients with metastatic breast cancer. ( Aravantinos, G; Bafaloukos, D; Fountzilas, G; Gogas, H; Kalofonos, HP; Koutras, A; Makatsoris, T; Mantzourani, M; Markopoulos, C; Onyenadum, A; Tzorakoelefterakis, E; Xiros, N, 2007) |
| "The purpose of this study was to determine the maximum-tolerated dose of gemcitabine plus mitoxantrone in women with metastatic breast cancer (MBC) and to evaluate activity and toxicity of this combination in a phase II trial." | 9.10 | Phase I/II study of gemcitabine plus mitoxantrone as salvage chemotherapy in metastatic breast cancer. ( Calabrese, P; Caporusso, L; Catino, A; Crucitta, E; D'Amico, C; De Lena, M; Guida, M; Latorre, A; Lorusso, V; Mazzei, A; Sambiasi, D; Schittulli, F; Silvestris, N, 2003) |
| "A multicenter phase III randomized study comparing the efficacies of two adjuvant polychemotherapeutic regimens in 145 patients with stage II node-positive breast cancer: the standard chemotherapy combination, CMF (cyclophosphamide, methotrexate, 5-fluorouracil), and an experimental protocol, CNF (cyclophosphamide, mitoxantrone [Novantrone], 5-fluorouracil) in which mitoxantrone replaced methotrexate." | 9.10 | CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus CNF (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant chemotherapy for stage II lymph-node positive breast cancer: results by demographic and clinical subgroups. ( Borovik, R; Brenner, HJ; Brenner, J; Catane, R; Chaitchik, S; Farbstein, H; Inbar, MJ; Peretz, T; Rizel, S; Ron, IG; Shani, A; Wigler, N, 2002) |
| "A phase II pilot study was carried out on 30 patients to ascertain the toxicity and efficacy of combination chemotherapy with mitoxantrone, methotrexate, 5-fluorouracil (NMF) in the adjuvant setting for axillary lymph node-positive breast cancer." | 9.09 | Adjuvant chemotherapy with a combination of mitoxantrone, methotrexate, 5-fluorouracil for node-positive breast cancer: phase II pilot study. ( Bando, H; Kanno, M; Kawahara, F; Mura, T; Nakamura, S; Noguchi, M; Taniya, T; Tsugawa, K; Uotani, C, 1999) |
| "Paclitaxel and mitoxantrone are highly active agents in the treatment of advanced breast cancer (ABC)." | 9.09 | Dose intensification of mitoxantrone in combination with paclitaxel in advanced breast cancer: a phase II study. ( Acito, L; Angiona, S; Bilancia, D; Costanzo, FD; Fioriti, L; Gasperoni, S; Giustini, L; Manzione, L; Sdrobolini, A; Valenti, L, 1999) |
| "Thirty-eight patients with stage II breast cancer with four or more positive axillary lymph nodes were randomized to receive CMF (cyclophosphamide, methotrexate and 5-fluorouracil, every 3 weeks) or CXF (cyclophosphamide, mitoxantrone and 5-fluorouracil, every 3 weeks)." | 9.07 | A preliminary report of a pilot randomized trial comparing cyclophosphamide, methotrexate and 5-fluorouracil with cyclophosphamide, mitoxantrone and 5-fluorouracil in the adjuvant therapy of stage II breast cancer with four or more positive axillary nodes ( Ben-Dor, CG; Brufman, G; Isacson, R; Safra, T; Uziely, B, 1993) |
| "The incidence of secondary myelodysplasia/acute myeloid leukemia (AML) was retrospectively assessed in an international joint study in 305 node-positive breast cancer patients, who received mitoxantrone-based high-dose chemotherapy (HDCT) followed by autologous stem cell support as adjuvant therapy." | 8.82 | Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients. ( Damon, L; Demirer, T; Derigs, G; Ferrante, P; Kröger, N; Rosti, G; Wandt, H; Zander, AR, 2003) |
| "We aimed to assess the safety and efficacy of mitoxantrone hydrochloride injection (MHI) for identifying axillary SLNs in patients with primary breast cancer." | 8.31 | Safety and Efficacy of Mitoxantrone Hydrochloride Injection for Identification of Axillary Sentinel Lymph Nodes in Patients with Primary Breast Cancer. ( Abdelaal, M; Elzayat, I; Monib, S, 2023) |
| "In an attempt to improve the therapeutic effect of mitoxantrone (MTO) against breast cancer and its lymph node metastases, solid lipid nanoparticles (SLN) of MTO were prepared, characterized and evaluated on mice." | 7.73 | Solid lipid nanoparticles of mitoxantrone for local injection against breast cancer and its lymph node metastases. ( Chao, RB; Lu, B; Xiong, SB; Yang, H; Yin, XD, 2006) |
| "The authors examined the survival rates of 60 patients with breast cancer who underwent parasternal lymph node biopsy during surgery with axillary lymph node dissection and had histologically confirmed axillary node metastasis followed by adjuvant doxorubicin- or mitoxantrone-containing combination chemotherapy to ascertain whether administration of anthracycline or its analogue improved the prognosis of both axillary and parasternal node-positive patients." | 7.70 | Prognosis of node-positive breast cancer patients who underwent parasternal lymph node biopsy during surgery followed by doxorubicin- or mitoxantrone-containing adjuvant chemotherapy. ( Kanno, M; Nakamura, S; Noguchi, M; Terasaki, Y; Tsugawa, K; Uotani, C; Yamanaka, S, 2000) |
| "A phase II study of mitoxantrone in cases of advanced breast cancer was conducted by a cooperative study group involving 7 institutions." | 7.67 | [Phase II study of mitoxantrone in advanced breast cancer]. ( Hoshino, A; Kubo, K; Nomura, Y; Ogawa, M; Ota, K; Taguchi, T; Tominaga, T; Yoshida, M, 1986) |
| "Grade 3/4 neutropenia was observed in 29 patients (58%) with four neutropenic episodes." | 6.69 | First-line treatment of metastatic breast cancer with mitoxantrone, vinorelbine, and carboplatin. ( Agelaki, S; Androulakis, N; Georgoulias, V; Hatzidaki, D; Kakolyris, S; Koukourakis, M; Kourousis, C; Samonis, G; Tsiftsis, D; Vamvakas, L, 1999) |
| "Mitoxantrone (MIT) is a new anthraquinone anticancer agent." | 5.30 | [Intra-arterial injection therapy of mitoxantrone for locally advanced breast cancer]. ( Ichikawa, W; Iida, S; Miyanaga, T; Nihei, Z; Nishi, N; Osanai, T; Shimizu, C; Sugihara, K; Togo, S; Uetake, H; Yamashita, T, 1998) |
| "In 117 primary breast cancers, 25 were amplified for erbB2." | 5.29 | Topoisomerase II alpha co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity. ( Carmichael, J; Greenall, M; Harris, AL; Houlbrook, S; Smith, K, 1993) |
| "The aim was to determine the recommended dose of combined chemotherapy with mitoxantrone and uracil/tegafur (Phase I part) and to clarify its efficacy and safety in patients with advanced hepatocellular carcinoma at the recommended dose (Phase II part)." | 5.15 | A phase I/II study of combined chemotherapy with mitoxantrone and uracil/tegafur for advanced hepatocellular carcinoma. ( Furuse, J; Ikeda, M; Ishii, H; Mitsunaga, S; Morizane, C; Nakachi, K; Okusaka, T; Suzuki, E; Ueno, H, 2011) |
| "Vinorelbine and mitoxantrone have both been demonstrated to have significant antitumor activity in patients with breast cancer." | 5.12 | Mitoxantrone plus vinorelbine in pretreated patients with metastatic breast cancer. ( Aravantinos, G; Bafaloukos, D; Fountzilas, G; Gogas, H; Kalofonos, HP; Koutras, A; Makatsoris, T; Mantzourani, M; Markopoulos, C; Onyenadum, A; Tzorakoelefterakis, E; Xiros, N, 2007) |
| "The present randomized phase III trial was designed to detect a 15% benefit in relapse-free survival (RFS) or overall survival (OS) from the incorporation of adjuvant tamoxifen to the combination of CNF [cyclophosphamide, 500 mg/m2; mitoxantrone (Novantrone), 10 mg/m2; fluorouracil, 500 mg/m2 chemotherapy and ovarian ablation in premenopausal patients with node-positive breast cancer and conversely from the incorporation of CNF chemotherapy to adjuvant tamoxifen in node-positive postmenopausal patients." | 5.11 | Adjuvant cytotoxic and endocrine therapy in pre- and postmenopausal patients with breast cancer and one to nine infiltrated nodes: five-year results of the Hellenic Cooperative Oncology Group randomized HE 10/92 study. ( Adamou, A; Bafaloukos, D; Ekonomopoulos, T; Fountzilas, G; Georgoulias, V; Kalofonos, HP; Klouvas, G; Kosmidis, P; Koukouras, D; Kouvatseas, G; Kyriakou, K; Pavlidis, N; Pectasidis, D; Polychronis, A; Razis, E; Samantas, E; Skarlos, D; Stathopoulos, G; Zamboglou, N; Zombolas, V, 2004) |
| "A multicenter phase III randomized study comparing the efficacies of two adjuvant polychemotherapeutic regimens in 145 patients with stage II node-positive breast cancer: the standard chemotherapy combination, CMF (cyclophosphamide, methotrexate, 5-fluorouracil), and an experimental protocol, CNF (cyclophosphamide, mitoxantrone [Novantrone], 5-fluorouracil) in which mitoxantrone replaced methotrexate." | 5.10 | CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus CNF (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant chemotherapy for stage II lymph-node positive breast cancer: results by demographic and clinical subgroups. ( Borovik, R; Brenner, HJ; Brenner, J; Catane, R; Chaitchik, S; Farbstein, H; Inbar, MJ; Peretz, T; Rizel, S; Ron, IG; Shani, A; Wigler, N, 2002) |
| "The purpose of this study was to determine the maximum-tolerated dose of gemcitabine plus mitoxantrone in women with metastatic breast cancer (MBC) and to evaluate activity and toxicity of this combination in a phase II trial." | 5.10 | Phase I/II study of gemcitabine plus mitoxantrone as salvage chemotherapy in metastatic breast cancer. ( Calabrese, P; Caporusso, L; Catino, A; Crucitta, E; D'Amico, C; De Lena, M; Guida, M; Latorre, A; Lorusso, V; Mazzei, A; Sambiasi, D; Schittulli, F; Silvestris, N, 2003) |
| "Paclitaxel and mitoxantrone are highly active agents in the treatment of advanced breast cancer (ABC)." | 5.09 | Dose intensification of mitoxantrone in combination with paclitaxel in advanced breast cancer: a phase II study. ( Acito, L; Angiona, S; Bilancia, D; Costanzo, FD; Fioriti, L; Gasperoni, S; Giustini, L; Manzione, L; Sdrobolini, A; Valenti, L, 1999) |
| "A phase II pilot study was carried out on 30 patients to ascertain the toxicity and efficacy of combination chemotherapy with mitoxantrone, methotrexate, 5-fluorouracil (NMF) in the adjuvant setting for axillary lymph node-positive breast cancer." | 5.09 | Adjuvant chemotherapy with a combination of mitoxantrone, methotrexate, 5-fluorouracil for node-positive breast cancer: phase II pilot study. ( Bando, H; Kanno, M; Kawahara, F; Mura, T; Nakamura, S; Noguchi, M; Taniya, T; Tsugawa, K; Uotani, C, 1999) |
| "Thirty-eight patients with stage II breast cancer with four or more positive axillary lymph nodes were randomized to receive CMF (cyclophosphamide, methotrexate and 5-fluorouracil, every 3 weeks) or CXF (cyclophosphamide, mitoxantrone and 5-fluorouracil, every 3 weeks)." | 5.07 | A preliminary report of a pilot randomized trial comparing cyclophosphamide, methotrexate and 5-fluorouracil with cyclophosphamide, mitoxantrone and 5-fluorouracil in the adjuvant therapy of stage II breast cancer with four or more positive axillary nodes ( Ben-Dor, CG; Brufman, G; Isacson, R; Safra, T; Uziely, B, 1993) |
| "The incidence of secondary myelodysplasia/acute myeloid leukemia (AML) was retrospectively assessed in an international joint study in 305 node-positive breast cancer patients, who received mitoxantrone-based high-dose chemotherapy (HDCT) followed by autologous stem cell support as adjuvant therapy." | 4.82 | Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients. ( Damon, L; Demirer, T; Derigs, G; Ferrante, P; Kröger, N; Rosti, G; Wandt, H; Zander, AR, 2003) |
| "We aimed to assess the safety and efficacy of mitoxantrone hydrochloride injection (MHI) for identifying axillary SLNs in patients with primary breast cancer." | 4.31 | Safety and Efficacy of Mitoxantrone Hydrochloride Injection for Identification of Axillary Sentinel Lymph Nodes in Patients with Primary Breast Cancer. ( Abdelaal, M; Elzayat, I; Monib, S, 2023) |
| "In an attempt to improve the therapeutic effect of mitoxantrone (MTO) against breast cancer and its lymph node metastases, solid lipid nanoparticles (SLN) of MTO were prepared, characterized and evaluated on mice." | 3.73 | Solid lipid nanoparticles of mitoxantrone for local injection against breast cancer and its lymph node metastases. ( Chao, RB; Lu, B; Xiong, SB; Yang, H; Yin, XD, 2006) |
| "The authors examined the survival rates of 60 patients with breast cancer who underwent parasternal lymph node biopsy during surgery with axillary lymph node dissection and had histologically confirmed axillary node metastasis followed by adjuvant doxorubicin- or mitoxantrone-containing combination chemotherapy to ascertain whether administration of anthracycline or its analogue improved the prognosis of both axillary and parasternal node-positive patients." | 3.70 | Prognosis of node-positive breast cancer patients who underwent parasternal lymph node biopsy during surgery followed by doxorubicin- or mitoxantrone-containing adjuvant chemotherapy. ( Kanno, M; Nakamura, S; Noguchi, M; Terasaki, Y; Tsugawa, K; Uotani, C; Yamanaka, S, 2000) |
| "14 patients with recurrent lymph node metastases in cases of breast cancer were presented to be treated by intraarterial chemotherapy of 25 mg mitoxantrone/m2 over a period of 24 hours." | 3.69 | [Superselective intra-arterial chemotherapy in therapy-refractory lymph node recurrences of breast carcinoma]. ( Brambs, HJ; Görich, J; Hasan, I; Krämer, S; Kunze, V; Rieber, A; Rilinger, N; Sokiranski, R, 1996) |
| "From October 1985 to November 1987, arterial regional chemotherapy with mitoxantrone was undertaken in 18 patients with primary far advanced carcinoma of the breast, of inflammatory or ulcerating type." | 3.67 | [Arterial regional chemotherapy of advanced breast cancer]. ( de Dycker, RP; Neumann, RL; Schindler, AE; Timmermann, J; Wever, H, 1988) |
| "A phase II study of mitoxantrone in cases of advanced breast cancer was conducted by a cooperative study group involving 7 institutions." | 3.67 | [Phase II study of mitoxantrone in advanced breast cancer]. ( Hoshino, A; Kubo, K; Nomura, Y; Ogawa, M; Ota, K; Taguchi, T; Tominaga, T; Yoshida, M, 1986) |
| "Treatment with mitoxantrone plus prednisone was associated with greater and longer-lasting improvement in several HQL domains and symptoms than treatment with prednisone alone." | 2.69 | Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. ( Ernst, DS; Neville, AJ; Osoba, D; Tannock, IF, 1999) |
| "Grade 3/4 neutropenia was observed in 29 patients (58%) with four neutropenic episodes." | 2.69 | First-line treatment of metastatic breast cancer with mitoxantrone, vinorelbine, and carboplatin. ( Agelaki, S; Androulakis, N; Georgoulias, V; Hatzidaki, D; Kakolyris, S; Koukourakis, M; Kourousis, C; Samonis, G; Tsiftsis, D; Vamvakas, L, 1999) |
| "Combined chemotherapy and radiotherapy in standard dosage is an acceptable approach following mastectomy for patients with extensive nodal involvement at high risk for local recurrence and distant relapse." | 2.68 | Combined chemotherapy and radiotherapy for patients with breast cancer and extensive nodal involvement. ( Barraclough, B; Boyages, J; Langlands, AO; Ung, O, 1995) |
| "Patients with metastatic breast cancer (MBC) (median follow-up, 1." | 2.41 | High-dose chemotherapy and hematopoietic stem cell rescue for breast cancer: experience in California. ( Blume, KG; Cecchi, GR; Damon, LE; Glaspy, J; Gold, E; Hu, WW; Irwin, D; Linker, CA; Mason, JR; Miller, W; Stockerl-Goldstein, KE; Territo, I; Wolf, JL, 2000) |
| "Locally advanced, fungating breast cancers pose particularly difficult management problems for which intra-arterial drug delivery may be appropriate in carefully, selected cases." | 2.39 | Intra-arterial chemotherapy for palliation of fungating breast cancer. A case report and review of the literature. ( Bufill, JA; Grace, WR; Neff, R, 1994) |
| "Finally, a lymphatic metastasis mice model was established to precede the pharmacodynamics of MTO NCs, and using MTO liposomes as a reference preparation, the inhibitory effect of MTO NCs on lymphatic metastasis was markedly higher." | 1.51 | A Novel Self-Assembly Nanocrystal as Lymph Node-Targeting Delivery System: Higher Activity of Lymph Node Targeting and Longer Efficacy Against Lymphatic Metastasis. ( Chen, G; Liu, J; Mao, Y; Shi, T; Wang, S, 2019) |
| "The long term outcome of women with breast carcinoma and isolated SCN metastases whose disease is sensitive to CT appears to be favorable; whether this result is superior to that achieved with standard therapy alone remains to be confirmed in prospective, randomized trials." | 1.31 | High dose chemotherapy and autologous blood stem cell support in women with breast carcinoma and isolated supraclavicular lymph node metastases. ( Abraham, R; Crump, M; Goss, PE; Nagy, T, 2000) |
| "152 of 211 breast cancer patients received post-operatively a combination chemotherapy including the anthracycline analog mitoxantrone, while 59 patients were treated with conventional CMF therapy." | 1.30 | Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients. ( Fehm, T; Jäger, W; Katalinic, A; Maimonis, P; Teramoto, Y; Weitz, S, 1997) |
| "Mitoxantrone (MIT) is a new anthraquinone anticancer agent." | 1.30 | [Intra-arterial injection therapy of mitoxantrone for locally advanced breast cancer]. ( Ichikawa, W; Iida, S; Miyanaga, T; Nihei, Z; Nishi, N; Osanai, T; Shimizu, C; Sugihara, K; Togo, S; Uetake, H; Yamashita, T, 1998) |
| "In 117 primary breast cancers, 25 were amplified for erbB2." | 1.29 | Topoisomerase II alpha co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity. ( Carmichael, J; Greenall, M; Harris, AL; Houlbrook, S; Smith, K, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (10.42) | 18.7374 |
| 1990's | 17 (35.42) | 18.2507 |
| 2000's | 19 (39.58) | 29.6817 |
| 2010's | 6 (12.50) | 24.3611 |
| 2020's | 1 (2.08) | 2.80 |
| Authors | Studies |
|---|---|
| Elzayat, I | 1 |
| Abdelaal, M | 1 |
| Monib, S | 1 |
| Mao, Y | 1 |
| Liu, J | 1 |
| Shi, T | 1 |
| Chen, G | 1 |
| Wang, S | 1 |
| Thomas, C | 1 |
| Brandt, MP | 1 |
| Baldauf, S | 1 |
| Tsaur, I | 1 |
| Frees, S | 1 |
| Borgmann, H | 1 |
| Jäger, W | 2 |
| Bartsch, G | 1 |
| Schneider, M | 1 |
| Dotzauer, R | 1 |
| Neisius, A | 1 |
| Haferkamp, A | 1 |
| Shi, R | 1 |
| Wang, C | 1 |
| Fu, N | 1 |
| Liu, L | 1 |
| Zhu, D | 1 |
| Wei, Z | 1 |
| Zhang, H | 1 |
| Xing, J | 1 |
| Wang, Y | 1 |
| Pedrazzoli, P | 1 |
| Martinelli, G | 1 |
| Gianni, AM | 1 |
| Da Prada, GA | 1 |
| Ballestrero, A | 1 |
| Rosti, G | 2 |
| Frassineti, GL | 1 |
| Aieta, M | 1 |
| Secondino, S | 1 |
| Cinieri, S | 1 |
| Fedele, R | 1 |
| Bengala, C | 1 |
| Bregni, M | 1 |
| Grasso, D | 1 |
| De Giorgi, U | 1 |
| Lanza, F | 1 |
| Castagna, L | 1 |
| Bruno, B | 1 |
| Martino, M | 1 |
| Zwick, C | 1 |
| Birkmann, J | 1 |
| Peter, N | 1 |
| Bodenstein, H | 1 |
| Fuchs, R | 1 |
| Hänel, M | 1 |
| Reiser, M | 1 |
| Hensel, M | 1 |
| Clemens, M | 1 |
| Zeynalova, S | 1 |
| Ziepert, M | 1 |
| Pfreundschuh, M | 1 |
| O'Brien, C | 1 |
| True, LD | 1 |
| Higano, CS | 1 |
| Rademacher, BL | 1 |
| Garzotto, M | 1 |
| Beer, TM | 1 |
| Suzuki, E | 1 |
| Furuse, J | 1 |
| Ikeda, M | 1 |
| Ishii, H | 1 |
| Okusaka, T | 1 |
| Nakachi, K | 1 |
| Mitsunaga, S | 1 |
| Ueno, H | 1 |
| Morizane, C | 1 |
| Ron, IG | 2 |
| Wigler, N | 2 |
| Borovik, R | 2 |
| Peretz, T | 1 |
| Rizel, S | 2 |
| Shani, A | 2 |
| Brenner, J | 2 |
| Farbstein, H | 2 |
| Brenner, HJ | 2 |
| Chaitchik, S | 2 |
| Catane, R | 2 |
| Inbar, MJ | 2 |
| Lorusso, V | 2 |
| Crucitta, E | 1 |
| Silvestris, N | 1 |
| Catino, A | 2 |
| Caporusso, L | 1 |
| Mazzei, A | 1 |
| Guida, M | 1 |
| Latorre, A | 1 |
| Sambiasi, D | 1 |
| D'Amico, C | 1 |
| Schittulli, F | 2 |
| Calabrese, P | 1 |
| De Lena, M | 2 |
| Petit, T | 1 |
| Borel, C | 1 |
| Theobald, S | 1 |
| Serin, D | 1 |
| Rodier, JF | 1 |
| Prevot, G | 1 |
| Brettes, JP | 1 |
| Klein, T | 1 |
| Kröger, N | 2 |
| Damon, L | 1 |
| Zander, AR | 2 |
| Wandt, H | 2 |
| Derigs, G | 1 |
| Ferrante, P | 1 |
| Demirer, T | 1 |
| Fountzilas, G | 2 |
| Stathopoulos, G | 1 |
| Kouvatseas, G | 1 |
| Polychronis, A | 1 |
| Klouvas, G | 1 |
| Samantas, E | 1 |
| Zamboglou, N | 1 |
| Kyriakou, K | 1 |
| Adamou, A | 1 |
| Pectasidis, D | 1 |
| Ekonomopoulos, T | 1 |
| Kalofonos, HP | 2 |
| Bafaloukos, D | 2 |
| Georgoulias, V | 2 |
| Razis, E | 1 |
| Koukouras, D | 1 |
| Zombolas, V | 1 |
| Kosmidis, P | 1 |
| Skarlos, D | 1 |
| Pavlidis, N | 1 |
| Calais, G | 1 |
| Yamanaka, K | 1 |
| Gleave, ME | 1 |
| Hara, I | 1 |
| Muramaki, M | 1 |
| Miyake, H | 1 |
| Lu, B | 3 |
| Xiong, SB | 3 |
| Yang, H | 3 |
| Yin, XD | 3 |
| Zhao, RB | 2 |
| Chao, RB | 1 |
| Yamauchi, C | 1 |
| Mitsumori, M | 1 |
| Sai, H | 1 |
| Imagunbai, T | 1 |
| Negoro, Y | 1 |
| Sasaki, Y | 1 |
| Hiraoka, M | 1 |
| Shikama, N | 1 |
| Sasaki, S | 1 |
| Takegawa, H | 1 |
| Inoue, T | 1 |
| Teshima, T | 1 |
| Onyenadum, A | 1 |
| Gogas, H | 1 |
| Markopoulos, C | 1 |
| Aravantinos, G | 1 |
| Mantzourani, M | 1 |
| Koutras, A | 1 |
| Tzorakoelefterakis, E | 1 |
| Xiros, N | 1 |
| Makatsoris, T | 1 |
| Schmoor, C | 1 |
| Krüger, W | 1 |
| Möbus, V | 1 |
| Frickhofen, N | 1 |
| Metzner, B | 1 |
| Berdel, WE | 1 |
| Koenigsmann, M | 1 |
| Thiel, E | 1 |
| Possinger, K | 1 |
| Kreienberg, R | 1 |
| Schumacher, M | 1 |
| Jonat, W | 1 |
| Bufill, JA | 1 |
| Grace, WR | 1 |
| Neff, R | 1 |
| Ung, O | 1 |
| Langlands, AO | 1 |
| Barraclough, B | 1 |
| Boyages, J | 1 |
| Smith, K | 1 |
| Houlbrook, S | 1 |
| Greenall, M | 1 |
| Carmichael, J | 1 |
| Harris, AL | 1 |
| Isacson, R | 1 |
| Safra, T | 1 |
| Ben-Dor, CG | 1 |
| Uziely, B | 1 |
| Brufman, G | 2 |
| Krämer, S | 1 |
| Görich, J | 1 |
| Hasan, I | 1 |
| Sokiranski, R | 1 |
| Kunze, V | 1 |
| Rieber, A | 1 |
| Rilinger, N | 1 |
| Brambs, HJ | 1 |
| Fehm, T | 1 |
| Maimonis, P | 1 |
| Weitz, S | 1 |
| Teramoto, Y | 1 |
| Katalinic, A | 1 |
| Barakat, RR | 1 |
| Fennelly, D | 1 |
| Pizzuto, F | 1 |
| Venkatraman, ES | 1 |
| Brown, C | 1 |
| Curtin, JP | 1 |
| Longo, S | 1 |
| Racanelli, A | 1 |
| Timurian, A | 1 |
| Marzullo, F | 1 |
| Simone, G | 1 |
| Brandi, M | 1 |
| Ichikawa, W | 1 |
| Osanai, T | 1 |
| Shimizu, C | 1 |
| Uetake, H | 1 |
| Iida, S | 1 |
| Yamashita, T | 1 |
| Nishi, N | 1 |
| Togo, S | 1 |
| Miyanaga, T | 1 |
| Nihei, Z | 1 |
| Sugihara, K | 1 |
| Deliĭski, T | 2 |
| Baĭchev, G | 2 |
| Popovska, S | 1 |
| Penkova, R | 1 |
| Polovska, S | 1 |
| Boĭkov, M | 1 |
| Costanzo, FD | 1 |
| Sdrobolini, A | 1 |
| Manzione, L | 1 |
| Bilancia, D | 1 |
| Acito, L | 1 |
| Gasperoni, S | 1 |
| Valenti, L | 1 |
| Fioriti, L | 1 |
| Angiona, S | 1 |
| Giustini, L | 1 |
| Chang, J | 1 |
| Powles, TJ | 1 |
| Allred, DC | 1 |
| Ashley, SE | 1 |
| Clark, GM | 1 |
| Makris, A | 1 |
| Assersohn, L | 1 |
| Gregory, RK | 1 |
| Osborne, CK | 1 |
| Dowsett, M | 1 |
| Osoba, D | 1 |
| Tannock, IF | 1 |
| Ernst, DS | 1 |
| Neville, AJ | 1 |
| Kakolyris, S | 1 |
| Kourousis, C | 1 |
| Koukourakis, M | 1 |
| Androulakis, N | 1 |
| Vamvakas, L | 1 |
| Agelaki, S | 1 |
| Hatzidaki, D | 1 |
| Samonis, G | 1 |
| Tsiftsis, D | 1 |
| Kanno, M | 2 |
| Nakamura, S | 2 |
| Uotani, C | 2 |
| Taniya, T | 1 |
| Mura, T | 1 |
| Bando, H | 1 |
| Kawahara, F | 1 |
| Tsugawa, K | 2 |
| Noguchi, M | 2 |
| Abraham, R | 1 |
| Nagy, T | 1 |
| Goss, PE | 1 |
| Crump, M | 1 |
| Damon, LE | 1 |
| Hu, WW | 1 |
| Stockerl-Goldstein, KE | 1 |
| Blume, KG | 1 |
| Wolf, JL | 1 |
| Gold, E | 1 |
| Cecchi, GR | 1 |
| Irwin, D | 1 |
| Glaspy, J | 1 |
| Territo, I | 1 |
| Miller, W | 1 |
| Mason, JR | 1 |
| Linker, CA | 1 |
| Yamanaka, S | 1 |
| Terasaki, Y | 1 |
| Fumoleau, P | 1 |
| Chauvin, F | 1 |
| Namer, M | 1 |
| Bugat, R | 1 |
| Tubiana-Hulin, M | 1 |
| Guastalla, JP | 1 |
| Delozier, T | 1 |
| Kerbrat, P | 1 |
| Devaux, Y | 1 |
| Bonneterre, J | 1 |
| Filleul, A | 1 |
| Clavel, M | 1 |
| Dale, A | 1 |
| Tamburini, M | 1 |
| Brambilla, C | 1 |
| Ferrari, L | 1 |
| Bombino, T | 1 |
| Gangeri, L | 1 |
| Rosso, S | 1 |
| Mulder, PO | 1 |
| Bouman, JG | 1 |
| Gietema, JA | 1 |
| Van Rijsbergen, H | 1 |
| Mulder, NH | 1 |
| Van der Geest, S | 1 |
| De Vries, EG | 1 |
| Büyükünal, E | 1 |
| Derman, U | 1 |
| Serdengecti, S | 1 |
| Berkarda, B | 1 |
| de Dycker, RP | 1 |
| Timmermann, J | 1 |
| Neumann, RL | 1 |
| Wever, H | 1 |
| Schindler, AE | 1 |
| Charrot, P | 1 |
| Chevrier, A | 1 |
| Ogawa, M | 1 |
| Kubo, K | 1 |
| Tominaga, T | 1 |
| Nomura, Y | 1 |
| Ota, K | 1 |
| Yoshida, M | 1 |
| Taguchi, T | 1 |
| Hoshino, A | 1 |
4 reviews available for mitoxantrone and Lymph Node Metastasis
| Article | Year |
|---|---|
Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantat | 2003 |
[Radiation and concomitant chemotherapy after surgery for breast cancer].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; An | 2004 |
Intra-arterial chemotherapy for palliation of fungating breast cancer. A case report and review of the literature.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Female; | 1994 |
High-dose chemotherapy and hematopoietic stem cell rescue for breast cancer: experience in California.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms; Calif | 2000 |
21 trials available for mitoxantrone and Lymph Node Metastasis
| Article | Year |
|---|---|
Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP r
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cycl | 2008 |
Histologic changes associated with neoadjuvant chemotherapy are predictive of nodal metastases in patients with high-risk prostate cancer.
Topics: Aged; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Lymph | 2010 |
A phase I/II study of combined chemotherapy with mitoxantrone and uracil/tegafur for advanced hepatocellular carcinoma.
Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carci | 2011 |
CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus CNF (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant chemotherapy for stage II lymph-node positive breast cancer: results by demographic and clinical subgroups.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp | 2002 |
Phase I/II study of gemcitabine plus mitoxantrone as salvage chemotherapy in metastatic breast cancer.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug | 2003 |
Randomized multicentric study of perioperative chemotherapy with mitoxantrone in early breast cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dis | 2003 |
Adjuvant cytotoxic and endocrine therapy in pre- and postmenopausal patients with breast cancer and one to nine infiltrated nodes: five-year results of the Hellenic Cooperative Oncology Group randomized HE 10/92 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The | 2004 |
[Radiation and concomitant chemotherapy after surgery for breast cancer].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; An | 2004 |
Mitoxantrone plus vinorelbine in pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brai | 2007 |
Randomized trial of high-dose adjuvant chemotherapy with autologous hematopoietic stem-cell support versus standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: overall survival after 6 years of follow-up.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyc | 2008 |
Combined chemotherapy and radiotherapy for patients with breast cancer and extensive nodal involvement.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplati | 1995 |
A preliminary report of a pilot randomized trial comparing cyclophosphamide, methotrexate and 5-fluorouracil with cyclophosphamide, mitoxantrone and 5-fluorouracil in the adjuvant therapy of stage II breast cancer with four or more positive axillary nodes
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubic | 1993 |
Neoadjuvant chemotherapy with accelerated CNF plus G-CSF in patients with breast cancer tumors larger than three centimeters: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The | 1998 |
Dose intensification of mitoxantrone in combination with paclitaxel in advanced breast cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; | 1999 |
Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol | 1999 |
First-line treatment of metastatic breast cancer with mitoxantrone, vinorelbine, and carboplatin.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplas | 1999 |
Adjuvant chemotherapy with a combination of mitoxantrone, methotrexate, 5-fluorouracil for node-positive breast cancer: phase II pilot study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; C | 1999 |
Intensification of adjuvant chemotherapy: 5-year results of a randomized trial comparing conventional doxorubicin and cyclophosphamide with high-dose mitoxantrone and cyclophosphamide with filgrastim in operable breast cancer with 10 or more involved axil
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Chemotherapy, | 2001 |
CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus cnf (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant chemotherapy for stage II lymph-node positive breast cancer: a phase III randomized multicenter study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2001 |
Hyperalimentation in autologous bone marrow transplantation for solid tumors. Comparison of total parenteral versus partial parenteral plus enteral nutrition.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Bone Marrow Transplantation; Com | 1989 |
A clinical trial of mitoxantrone (novantrone) versus doxorubicin (adriamycin) in combination chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Clini | 1987 |
24 other studies available for mitoxantrone and Lymph Node Metastasis
| Article | Year |
|---|---|
Safety and Efficacy of Mitoxantrone Hydrochloride Injection for Identification of Axillary Sentinel Lymph Nodes in Patients with Primary Breast Cancer.
Topics: Axilla; Breast Neoplasms; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Mitoxantrone; Prospecti | 2023 |
A Novel Self-Assembly Nanocrystal as Lymph Node-Targeting Delivery System: Higher Activity of Lymph Node Targeting and Longer Efficacy Against Lymphatic Metastasis.
Topics: Animals; Antineoplastic Agents; Liposomes; Lymph Nodes; Lymphatic Metastasis; Mice; Mitoxantrone; Na | 2019 |
Docetaxel-rechallenge in castration-resistant prostate cancer: defining clinical factors for successful treatment response and improvement in overall survival.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease-Free Surv | 2018 |
Downregulation of cytokeratin 18 enhances BCRP-mediated multidrug resistance through induction of epithelial-mesenchymal transition and predicts poor prognosis in breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast; | 2019 |
Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell support for high-risk primary breast cancer: results from the Italian national registry.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brea | 2014 |
Synergistic antitumor effect of combined use of adenoviral-mediated p53 gene transfer and antisense oligodeoxynucleotide targeting clusterin gene in an androgen-independent human prostate cancer model.
Topics: Adenoviridae; Androgens; Animals; Apoptosis; Cell Line, Tumor; Clusterin; Combined Modality Therapy; | 2005 |
Mitoxantrone-loaded BSA nanospheres and chitosan nanospheres for local injection against breast cancer and its lymph node metastases. II: Tissue distribution and pharmacodynamics.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chemistry, Pharmaceutical; Chitosan; Female; Human | 2006 |
Mitoxantrone-loaded BSA nanospheres and chitosan nanospheres for local injection against breast cancer and its lymph node metastases. I: Formulation and in vitro characterization.
Topics: Antineoplastic Agents; Breast Neoplasms; Chemistry, Pharmaceutical; Chitosan; Drug Stability; Freeze | 2006 |
Solid lipid nanoparticles of mitoxantrone for local injection against breast cancer and its lymph node metastases.
Topics: Algorithms; Animals; Antineoplastic Agents; Body Weight; Breast Neoplasms; Cell Line, Tumor; Chlorof | 2006 |
Patterns of care study of breast-conserving therapy in Japan: comparison of the treatment process between 1995 1997 and 1999 2001 surveys.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2007 |
Topoisomerase II alpha co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity.
Topics: Adult; Aged; Amsacrine; Breast Neoplasms; DNA Topoisomerases, Type II; DNA, Neoplasm; ErbB Receptors | 1993 |
[Superselective intra-arterial chemotherapy in therapy-refractory lymph node recurrences of breast carcinoma].
Topics: Adult; Aged; Angiography; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Infusions, Intra- | 1996 |
Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Case-Control Studies; Chemotherapy | 1997 |
Salvage intraperitoneal therapy of advanced epithelial ovarian cancer: impact of retroperitoneal nodal disease.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogen | 1997 |
[Intra-arterial injection therapy of mitoxantrone for locally advanced breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Catheters, Indwelling; Combined Mo | 1998 |
[The lymphotropic marking and biopsy of sentinel lymph nodes in T1 tumors--a new approach to the staging of axillary lymphatic metastasis in breast cancer].
Topics: Anthraquinones; Antineoplastic Agents; Axilla; Biopsy; Breast Neoplasms; Carcinoma; Coloring Agents; | 1997 |
[Regional lymphotropic chemotherapy in breast cancer--a new approach in the therapeutic procedure for the parasternal lymph nodes].
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 1998 |
Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; DN | 1999 |
High dose chemotherapy and autologous blood stem cell support in women with breast carcinoma and isolated supraclavicular lymph node metastases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Combined Modal | 2000 |
Prognosis of node-positive breast cancer patients who underwent parasternal lymph node biopsy during surgery followed by doxorubicin- or mitoxantrone-containing adjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Axilla; Biopsy; Breast Neoplasms; Chemotherapy, Adjuvant; Combin | 2000 |
Two simple indexes used to evaluate the impact of therapy on the quality of life of patients receiving primary chemotherapy for operable breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp | 1991 |
[Arterial regional chemotherapy of advanced breast cancer].
Topics: Breast Neoplasms; Carcinoma; Combined Modality Therapy; Drug Evaluation; Female; Humans; Infusions, | 1988 |
[Mitoxantrone in metastatic cylindromas. Apropos of a case].
Topics: Adult; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Mitoxantrone; Neoplasm Recurrence, Loca | 1987 |
[Phase II study of mitoxantrone in advanced breast cancer].
Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Drug Administration Schedule; | 1986 |